dolutegravir/lamivudine vs metformin
According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.
Side-by-side comparison of dolutegravir/lamivudine and metformin. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
moderate Known Drug Interaction
7.2 Potential for DOVATO to Affect Other Drugs Dolutegravir, a component of DOVATO, inhibits the renal organic cation transporters (OCT)2 and multidrug and toxin extrusion transporter (MATE)1; thus, it may increase plasma concentrations of drugs eliminated via OCT2 or MATE1 such as dofetilide, dalfampridine, and metformin [see Contraindications ( 4 ), Drug Interactions ( 7.4 ), Clinical Pharmacology ( 12.3 )]. Antidiabetic: Metformin a ↑Metformin Refer to the prescribing information for metformin for assessing the benefit and risk of concomitant use of DOVATO and metformin.
Dovato
Glucophage, Fortamet, Glumetza
Dovato is a complete HIV-1 treatment that combines two medicines into one tablet. It is used for adults and adolescents who weigh at least 55 pounds.
No summary available.
Dovato is used to treat HIV-1 infection in adults and adolescents (12 years and older, weighing at least 55 pounds). It can be used if you have never taken HIV-1 medicines before. It can also be used to replace your current HIV-1 medicines if your virus is under control (HIV-1 RNA less than 50 copies/mL) and you have not had treatment failure or resistance to the medicines in Dovato.
Information not available.
Dovato contains two drugs: dolutegravir and lamivudine. Dolutegravir blocks HIV-1 integrase, an enzyme the virus needs to multiply. Lamivudine blocks reverse transcriptase, another enzyme HIV-1 needs to make copies of itself.
Information not available.
- • Headache
- • Nausea
- • Diarrhea
- • Trouble sleeping (insomnia)
- • Tiredness (fatigue)
- • Diarrhea
- • Upper respiratory tract infection (like a cold)
- • Headache
- Pain 1,425
- Anxiety 1,051
- Emotional Distress 1,048
- Anhedonia 942
- Chronic Kidney Disease 701
- Nausea 21,946
- Diarrhoea 21,884
- Blood Glucose Increased 18,328
- Fatigue 17,252
- Acute Kidney Injury 16,440
If you have both HIV-1 and hepatitis B, you should be tested for hepatitis B before starting Dovato. Using Dovato can cause the hepatitis B virus to become resistant to lamivudine. Stopping Dovato can also cause a severe worsening of hepatitis B. Your liver function should be checked regularly.
No specific warnings noted.
There is a pregnancy registry to monitor outcomes in people exposed to Dovato during pregnancy. Talk to your doctor if you are pregnant or plan to become pregnant. There may be a risk of neural tube defects if dolutegravir is taken at the time of conception.
No pregnancy information available.
Also Compare, Nearby Drugs
Compare dolutegravir/lamivudine with
How to Read This dolutegravir/lamivudine vs metformin Comparison
dolutegravir/lamivudine is classified in the Integrase Inhibitor / NRTI Combination drug class, while metformin sits within the Biguanide class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, dolutegravir/lamivudine has 5,167 submissions while metformin has 95,850. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known moderate interaction flagged in FDA labeling, attributed to dolutegravir blocks the proteins that help your kidneys remove metformin, which can lead to higher levels of metformin in your blood.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for dolutegravir/lamivudine or metformin.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.